Catalist-listed SIAMH may have gone public before it was ready – MAS review group should figure out why
Can the enablers of public listings be incentivised to ensure that companies do not come to market without a credible growth story?
WHEN news broke earlier this month that the external auditors of the Singapore Institute of Advanced Medicine Holdings (SIAMH) had issued a disclaimer of opinion on its latest financial statements, I imagined that the company’s share price would immediately plummet.
Then, I looked at my trading screen and realised the stock could not plummet because it was already on the floor – and had been for some time.
SIAMH listed on Catalist on Feb 16, following an initial public offering (IPO) at S$0.23 per share. It ended its first trading day at S$0.19. Less than a fortnight later, its shares had crashed below S$0.10.
TRENDING NOW
Johor property old hand KSL readies family handover amid market boom
Seatrium eyes S$28 billion in project opportunities amid global race for energy security
China targets offshore billions in biggest crackdown in decades
Trek 2000 shares jump 26% after Osim founder Ron Sim drops claims, sells 7.3% stake to Azure Capital